What is the optimum technique for delivering botulinum toxin to the bladder? Injection techniques vary worldwide and are unstandardized, and there is no consensus regarding whether technique actually matters. Most specialists believe that location and depth of injection is unlikely to alter efficacy, but studies have both confirmed and disputed these opinions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kuo, H. C. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J. Urol. 178, 1359–1363 (2007).
Lucioni, A., Rapp, D. E., Gong, E. M., Fedunok, P. & Bales, G. T. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can. J. Urol. 13, 3291–3295 (2006).
Abdel-Meguid, T. A. Botulinum toxin-A injections into neurogenic overactive bladder—to include or exclude the trigone? A prospective, randomized, controlled trial. J. Urol. 184, 2423–2428 (2010).
Manecksha, R. P. et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur. Urol. doi: 10.1016/j.eururo.2011.10.043.
Karsenty, G. et al. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J. Urol. 177, 1011–1014 (2007).
Mascarenhas, F., Cocuzza, M., Gomes, C. M. & Leao, N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol. Urodyn. 27, 311–314 (2008).
Apostolidis, A., Dasgupta, P. & Fowler, C. J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. 49, 644–650 (2006).
Kuo, H. C. Bladder base/trigone injection is safe and as effective as bladder body injection of OnabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol. Urodyn. 30, 1242–1248 (2011).
Krhut, J. & Zvara, P. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int. Urol. Nephrol. 43, 337–343 (2011).
Chuang, Y. C. et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J. Urol. 182, 786–792 (2009).
Acknowledgements
A. Sahai and P. Dasgupta acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Center award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. They also acknowledge the support of the MRC Center for Transplantation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. Sahai and P. Dasgupta have received an unrestricted educational grant from and have been investigators for Allergan Ltd. A. Sahai has received honoraria for speaking on behalf of Allergan, Ltd. P. Dasgupta was a consultant for Allergan, Ltd.
Rights and permissions
About this article
Cite this article
Sahai, A., Dasgupta, P. Should we inject the trigone during botulinum toxin injection?. Nat Rev Urol 9, 129–130 (2012). https://doi.org/10.1038/nrurol.2012.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.1
